Innocan Pharma Announces First Half Of 2025 Financial Results

HERZLIYA, Israel and CALGARY, AB, Aug. 27, 2025 /CNW/ -- Innocan Pharma Corporation (CSE:INNO) (FSE: IP4) (OTC:INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce its financial consolidated results for the six months ended June 30, 2025. This period delivered a positive swing in Innocan's operating profitability together with continued strengthening of its balance sheet.

Iris Bincovich, CEO of Innocan, said:

"Despite a challenging market environment in the first half of 2025, we remain fully focused on executing our strategic vision across multiple target markets delivering effective, month-long relief from chronic pain for both humans and animals, with an opioid-free alternative, In addition, our Consumer Wellness segment presents significant opportunities for future growth.

First Half Of 2025 Financial Highlights

Revenues decreased 4% in the first half of 2025 to US$14.8M, compared to US$15.4M in the first half of 2024. The revenue decline was attributed to the uncertainty and volatility of the markets as a result of global trade tariffs.

 

Gross Profit decreased 4.9% in the first half of 2025 to US$13.3M compared to US$14.M in the first half of 2024.

           

Operating Profit increased by 130% to US$0.885M in the first half of 2025, compared to operating loss of US$0.680M in the first half of 2024.

 

Iris Bincovich CEO of Innocan, added: "We are progressing towards the next important milestone following the public filing of Registration Statement for our proposed U.S. public offering, and Innocan has applied to list its Common Shares and Warrants on the Nasdaq Capital Market under the symbols "INNP" and "INNPW", respectively. This opens up exciting new opportunities on multiple levels."

Roni Kamhi, CEO of BI Sky Global, and COO of ...